ROYALTY AGREEMENT BETWEEN LEAP THERAPEUTICS, INC. AND LEAP SHAREHOLDER ROYALTY VEHICLE, LLCRoyalty Agreement • January 26th, 2017 • Leap Therapeutics, Inc. • Pharmaceutical preparations
THIS ROYALTY AGREEMENT (this “Agreement”) is entered into as of January 23, 2017 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (“Company” or “Leap”), and Leap Shareholder Royalty Vehicle, LLC, a Delaware limited liability company (“Leap SRV”). Company and Leap SRV are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 26th, 2017 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT, dated this 23rd day of January, 2017 (this “Agreement”), is entered into by and among Leap Therapeutics Inc., a Delaware corporation, f/k/a Dekkun Corporation and HealthCare Pharmaceuticals, Inc. (the “Corporation”), and (i) those holders of Common Stock, par value $0.001 per share, of the Corporation (the “Common Stock”) listed on Schedule 1 hereto (collectively, the “Original Holders” and, each individually, an “Original Holder”) and (ii) those holders of Common Stock who become party to this Agreement pursuant to Section 10 hereof (collectively, the “Additional Holders” and, each individually, an “Additional Holder”). Collectively, the Original Holders and the Additional Holders shall be referred to herein collectively as the “Holders”, and each individually shall be referred to as a “Holder”).
LETTER AGREEMENTLetter Agreement • January 26th, 2017 • Leap Therapeutics, Inc. • Pharmaceutical preparations
This Letter Agreement (“Letter Agreement”) is entered into as of January 23, 2017, by and among Leap Therapeutics, Inc., a Delaware corporation (“Leap”), Leap Shareholder Royalty Vehicle, LLC, a Delaware limited liability company (“Leap SRV”), HealthCare Ventures VIII, L.P., a Delaware limited partnership (“HCV VIII”), HealthCare Ventures IX, L.P., a Delaware limited partnership (“HCV IX”), HealthCare Strategic Fund, L.P., a Delaware limited partnership (“HCV Strategic”), and Eli Lilly and Company, an Indiana corporation (“Lilly” and, together with HCV VIII, HCV IX and HCV Strategic, the “Initial Members”).
SUBSCRIPTION AGREEMENTSubscription Agreement • January 26th, 2017 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Subscription Agreement (this “Agreement”) is made as of January 23, 2017, by and between Leap Therapeutics, Inc., a Delaware company (the “Company”), and HealthCare Ventures IX, L.P., a Delaware limited partnership (the “Subscriber”).
